34820 Real-world treat-to-target skin clearance with risankizumab in patients with moderate to severe psoriasis from the CorEvitas Psoriasis Registry

Abstract

Objective: Risankizumab is efficacious in the treatment of plaque psoriasis, with a reported 73%–75% of patients receiving risankizumab vs 2%–5% receiving placebo achieving Psoriasis Area Severity Index ≥90% improvement at week 16. This analysis assessed real-world effectiveness of risankizumab in achieving National Psoriasis Foundation (NPF)-defined treatment targets. Methods: CorEvitas’ Psoriasis Registry is an independent, prospective, observational cohort of patients ≥18 years diagnosed with psoriasis by a dermatologist and recruited from practices in US and Canada. Adult patients with moderate-to-severe plaque psoriasis (Investigator’s Global Assessment ≥3) at baseline, who initiated risankizumab at baseline visit and had persistent use at 12-month ( ± 3 months) follow-up were included. The achievement of NPF-defined target response (body surface area [BSA] ≤1%) or acceptable response (BSA ≤3% or BSA improvement ≥75% from baseline) at 12 months after initiation was assessed (3). Results: Among 137 patients, mean (SD) age was 48.7 (14.0) years, 59.9% were male, and mean (SD) psoriasis duration was 15.3 (13.0) years at baseline. Mean (SD) BSA involvement was 13.8% (12.8%) and 62.0% of patients had prior biologic use at baseline. At 12 months (n = 136), 70.4% of patients achieved NPF-defined target and 90.4% achieved NPF-defined acceptable response. NPF-defined target and acceptable responses were achieved by 80% and 94% of biologic-naive patients (n = 52) and 64% and 88% of biologic-experienced patients (n = 85), respectively, at 12 months. Conclusion: Persistent 12-month risankizumab use was highly effective in achieving NPF-defined patient-centered treatment targets among patients with moderate-to-severe psoriasis in a real-world setting.